Showing results (21-30 of 89) with videos related to
Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|December 2, 2010
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patientsJonathan Hebb, Sarit Assouline, Caroline Rousseau, et al.Current Oncology (Toronto, Ont.)|October 27, 2022
Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive ChemotherapyDavid Sanford, Pierre Desjardins, Brian Leber, et al.Leukemia & Lymphoma|April 25, 2007
Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop CriteriaSarit Assouline, Ralph M Meyer, Claire Infante-Rivard, et al.Translational Oncology|August 3, 2021
CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell LymphomaRaoul Santiago, Johanna Ortiz Jimenez, Reza Forghani, et al.British Journal of Clinical Pharmacology|April 23, 2015
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemiaSarit Assouline, Valeria Buccheri, Alain Delmer, et al.Leukemia & Lymphoma|January 12, 2019
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 studyFarrukh T Awan, Michael J Thirman, Dipti Patel-Donnelly, et al.Clinical Lymphoma, Myeloma & Leukemia|June 24, 2018
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell LymphomaJohn M Burke, Andrei Shustov, James Essell, et al.Journal of Molecular Biology|December 3, 2023
Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in CellsMichael J Osborne, Anamika Sulekha, Biljana Culjkovic-Kraljacic, et al.Haematologica|March 23, 2023
Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabineSarit Assouline, Jadwiga Gasiorek, Julie Bergeron, et al.The Lancet. Haematology|March 8, 2016
Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trialSarit Assouline, Valeria Buccheri, Alain Delmer, et al.Pageof 9